【摘要】 通过参与诊治1例经皮冠状动脉介入术(percutaneous coronary intervention,PCI)抗栓治疗后重度血小板减少症患者,探讨该类型患者的临床治疗思维及药学监护方法。根据患者的实验室检查结果和临床表现,确定患者为药源性血小板减少症,由替罗非班引起的可能性大。经停用替罗非班、依诺肝素等抗栓药物,并给予丙种球蛋白、甲泼尼龙治疗后,患者血小板数量恢复正常后出院。临床药师积极参与临床诊治,有利于患者的用药安全。更多还原

【Abstract】 Pharmacists participated in the diagnosis and treatment of a patient with severe thrombocytopenia after percutaneous coronary intervention(PCI) antithrombotic therapy, and explored the clinical thinking and pharmaceutical monitoring of such patients. According to the patient’s laboratory test and clinical manifestations, we determined that the patient suffered drug-induced thrombocytopenia, and tirofiban had high possibility. After discontinuation of anti-thrombotic drugs such as tirofiban and enoxaparin, and replaced treatment with gamma globulin and methylprednisolone, the patient’s platelet count returned to normal before discharge. Clinical pharmacists actively participate in clinical diagnosis and treatment, which is conducive to the safe drug use inpatients.更多还原